The present invention provides novel fluorinated ether compounds having structure I
wherein R
1
is a C
2
-C
10
fluorinated aliphatic radical; R
2
is a C
1
-C
10
aliphatic radical, or a C
3
-C
10
cycloaliphatic radical; R
3
is hydrogen or a C
1
-C
10
aliphatic radical; and R
4
is hydrogen or a C
1
-C
10
aliphatic radical. The fluorinated ether compounds are provided in both racemic and enantiomerically enriched forms and may comprise either or both of fluorine-18 and fluorine 19. The fluorinated ether compounds are shown to possess high affinity for VMAT-2, a biomarker implicated in human diabetes. The fluorinated ether compounds comprising a fluorine-18 group are useful as PET imaging agents targeting the VMAT-2 biomarker. The non-radiolabeled fluorinated ether compounds are useful as probes for the discovery of PET imaging agents.
本发明提供了具有结构I的新型
氟化醚化合物,其中R1是C2-C10
氟代脂肪基;R2是C1-C10脂肪基,或C3-C10环脂肪基;R3是氢或C1-C10脂肪基;R4是氢或C1-C10脂肪基。这些
氟化醚化合物以消旋和对映富集形式提供,并且可能包含
氟-18和
氟-19中的任一个或两者。已证明这些
氟化醚化合物具有高亲和力VMAT-2,这是与人类糖尿病有关的
生物标志物。含有
氟-18基团的
氟化醚化合物可用作PET成像剂,以靶向VMAT-2
生物标志物。非放射性标记的
氟化醚化合物可用作发现PET成像剂的探针。